NAUTILUS BIOTECHNOLOGY, INC.

Analyst Reco. Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
2.49 ^USD	+5.51%		+1.22%	-16.72%

28/02	Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024
28/02	Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept	04/22/04	MT
Morgan Stanley Lowers Nautilus Biotechnology's Price Target to $6 From $8, Maintains Equalweight Rating	03/22/03	MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $4 from $5, Keeps Neutral Rating	14/22/14	MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $5 from $9, Keeps Neutral Rating	13/22/13	MT
Morgan Stanley Initiates Nautilus Biotechnology at Equalweight With $8 Price Target, Sees Commercialization Key to Unlocking Upside	06/22/06	MT
Cowen Initiates Coverage on Nautilus Biotechnology With Outperform Rating	02/21/02	MT
NAUTILUS BIOTECHNOLOGY : Goldman Sachs Starts Nautilus Biotechnology at Neutral With $10 Price Target	04/21/04	MT
NAUTILUS BIOTECHNOLOGY : Jefferies Starts Nautilus Biotechnology at Buy With $13 Price Target	13/21/13	MT
NAUTILUS BIOTECHNOLOGY : Jefferies Initiates Coverage on Nautilus Biotechnology With Buy Rating, $13 Price Target	13/21/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer